ClinicalTrials.gg
CompletedNCT00036283Updated Sep 29, 2008

Chemoprevention of Oral Premalignant Lesions

A Phase 2 interventional study of Celecoxib in Precancerous Conditions, sponsored by Pfizer. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-09-29.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 151 studies in Precancerous Conditions with a site in United States — 6 open to participants now, 12 under way, 2 of them phase 3. Precancerous Conditions · United States.

Enrollment
64th of 105
42 · median 58
Started
2000
with 5 others
Phase 2
44 of 151
1 open now
Registered
32nd of 151
by date

Among the 151 studies in Precancerous Conditions with a site in United States, this one is the 64th largest by enrollment of the 105 interventional ones that give a count, is one of 6 that started in 2000, is one of 44 in phase 2, and was the 32nd registered.

Precancerous Conditions

217 studies on the registry are indexed under Precancerous Conditions; 16 are open to participants now.

Browse Precancerous Conditions studies →

Open to participants now

6 of the 151 studies in Precancerous Conditions with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Precancerous Conditions studies recruiting now, 6 (50%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Precancerous Conditions with a site in United States, or all of them as a file.
02

Study summary

Reduction in size and number of oral premalignant lesions

03

Conditions studied

  • Precancerous Conditions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 8mm oral premalignant lesion that has not been biopsied in the past 6 months

Exclusion criteria

Exclusion Criteria:

  • Taking >100mg daily dose of NSAIDS (Non-steroidal anti-inflammatory drugs)
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
42 participants

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of celecoxib in subjects with Early or Advanced oral premalignant lesion (OPL)

  2. by both clinical response (reduction in size of all lesions,

  3. prevention of growth in the index lesion and of any new lesions)

  4. and histological response (change in histological grade).

  5. To evaluate the safety of chronic multiple dosing of celecoxib in this patient population.

Secondary outcomes

  1. To evaluate the treatment effects in modulating the expression of genomic and proliferative markers after 12 weeks of treatment with study drug, followed by 12 weeks off study drug.

07

Study locations

7 sites
  • Pfizer Investigational Site
    Farmington, Connecticut 06030-3805, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71103, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Pfizer Investigational Site
    New York, New York, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Seattle, Washington 98195-6607, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2000 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2002
First posted
May 9, 2002
Start
Nov 2000
CompletionActual
Apr 2004
Last update
Sep 29, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00036283
Lead sponsor
Pfizer
First posted
May 9, 2002
Start date
Nov 2000
Completion
Apr 2004
Last update
Sep 29, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion